Sio Capital Management, LLC
13F Reported Value
ⓘ$697.3M
incl. option notional
Equity Holdings
ⓘ$693.9M
Option Notional
ⓘ$3.4M
$3.4M puts / $0 calls
Holdings
76
Latest Filing
2026-03-31
Filing Quarter
Q1 2026
Portfolio Overview
Sio Capital Management, LLC disclosed 76 positions worth $697.3M in its Form 13F-HR for Q1 2026 — $693.9M in common stock plus $3.4M of put/call option positions (reported at underlying notional value, not premium at risk), led by $MMS (MAXIMUS, INC.) at 7.1% of the equity portfolio, followed by $WAY and $ICLR. During the quarter the fund opened 22 new positions and exited 14 — including a new stake in $CORT and a full exit from $CI. The portfolio is most concentrated in Healthcare (79.7% of disclosed assets). All figures are sourced directly from Sio Capital Management, LLC’s Form 13F-HR filing with the SEC under CIK 1482416.
AI Fund Analysis
DiversifyingSector Allocation
AUM History
Top Equity Holdings by Value
Option Positions
13F rules report options at the value of the underlying shares (notional) — not the premium paid or capital at risk. Shown separately from the equity sleeve above.
Quarterly Activity — Q1 2026
Click any card to unlockTop Holdings
- 57.4#1,047
Quality
$49.3M768,825 sh - 71.4#264
Quality
$39.6M1,642,236 sh - —
Quality
$33.9M306,358 sh - 59.6
Quality
$31.7M100,894 sh - 26.8
Quality
$31.1M370,045 sh - $29.9M5,382,965 sh
- 55.4
Quality
$27.2M674,759 sh - —
Quality
$26.8M421,615 sh - —
Quality
$23.2M605,439 sh - —
Quality
$22.1M193,843 sh
| Company | Quality | Value | Shares |
|---|---|---|---|
 MAXIMUS, INC.$MMS | 57.4#1,047 | $49.3M | 768,825 |
 Waystar Holding Corp.$WAY | 71.4#264 | $39.6M | 1,642,236 |
 ICON PLC$ICLR | — | $33.9M | 306,358 |
 Cencora, Inc.$COR | 59.6 | $31.7M | 100,894 |
 Dianthus Therapeutics, Inc. /DE/$DNTH | 26.8 | $31.1M | 370,045 |
 Anteris Technologies Global Corp.$AVR | — | $29.9M | 5,382,965 |
 CORCEPT THERAPEUTICS INC$CORT | 55.4 | $27.2M | 674,759 |
 LivaNova PLC$LIVN | — | $26.8M | 421,615 |
 Tyra Biosciences, Inc.$TYRA | — | $23.2M | 605,439 |
 Celcuity Inc.$CELC | — | $22.1M | 193,843 |
Unlock AI quality scores for every holding
32-signal composite ranking on each of Sio Capital Management, LLC's 76 positions.
Showing top 10 of 76 holdings.
Sector Allocation
Healthcare
$552.9M
Industrials
$59.6M
Technology
$49.7M
Consumer Staples
$31.7M
Full Holdings — Sio Capital Management, LLC (Q1 2026)
All 76 disclosed positions from the latest Form 13F-HR, with quarter-over-quarter share changes and 13F Pro quality scores. Sourced from SEC EDGAR.
| # | Ticker | Company | Value | Weight | QoQ | Quality |
|---|---|---|---|---|---|---|
| 1 | $MMS | MAXIMUS, INC. | $49.3M | 7.1% | +54% | 57.4 |
| 2 | $WAY | Waystar Holding Corp. | $39.6M | 5.7% | +168% | 71.4 |
| 3 | $ICLR | ICON PLC | $33.9M | 4.9% | +141% | — |
| 4 | $COR | Cencora, Inc. | $31.7M | 4.6% | +535% | 59.6 |
| 5 | $DNTH | Dianthus Therapeutics, Inc. /DE/ | $31.1M | 4.5% | -22% | 26.8 |
| 6 | $AVR | Anteris Technologies Global Corp. | $29.9M | 4.3% | +187% | — |
| 7 | $CORT | CORCEPT THERAPEUTICS INC | $27.2M | 3.9% | NEW | 55.4 |
| 8 | $LIVN | LivaNova PLC | $26.8M | 3.9% | +31% | — |
| 9 | $TYRA | Tyra Biosciences, Inc. | $23.2M | 3.3% | +15% | — |
| 10 | $CELC | Celcuity Inc. | $22.1M | 3.2% | -59% | — |
| 11 |  $GSK | GSK plc | $21.3M | 3.1% | NEW | — |
| 12 |  $ANIP | ANI PHARMACEUTICALS INC | $20.4M | 2.9% | +204% | 68.6 |
| 13 |  $ABT | ABBOTT LABORATORIES | $19.2M | 2.8% | NEW | 67 |
| 14 |  $EMBC | Embecta Corp. | $16.3M | 2.4% | NEW | 60.2 |
| 15 |  $ABVX | Abivax S.A. | $15.1M | 2.2% | +215% | — |
| 16 |  $VIR | Vir Biotechnology, Inc. | $13.4M | 1.9% | +213% | 5.6 |
| 17 |  $HAE | HAEMONETICS CORP | $12.4M | 1.8% | +138% | 61.1 |
| 18 |  $SION | Sionna Therapeutics, Inc. | $11.8M | 1.7% | NEW | — |
| 19 |  $SNY | Sanofi | $11.5M | 1.7% | -75% | — |
| 20 |  $RAPP | Rapport Therapeutics, Inc. | $11.5M | 1.6% | +98% | — |
| 21 |  $TFX | TELEFLEX INC | $11.3M | 1.6% | +9% | 30.5 |
| 22 |  $BMRN | BIOMARIN PHARMACEUTICAL INC | $11.0M | 1.6% | -17% | 74.1 |
| 23 |  $CCRN | CROSS COUNTRY HEALTHCARE INC | $10.3M | 1.5% | +3% | 34.5 |
| 24 |  $TARA | Protara Therapeutics, Inc. | $10.3M | 1.5% | +15% | — |
| 25 |  $GPCR | Structure Therapeutics Inc. | $10.1M | 1.4% | +4% | — |
| 26 |  $BHVN | Biohaven Ltd. | $9.8M | 1.4% | -6% | — |
| 27 |  $MNPR | Monopar Therapeutics | $9.5M | 1.4% | NEW | — |
| 28 |  $EYPT | EyePoint, Inc. | $9.3M | 1.3% | NEW | 10.3 |
| 29 |  $CRNX | Crinetics Pharmaceuticals, Inc. | $9.1M | 1.3% | +100% | 26.5 |
| 30 |  $EWTX | Edgewise Therapeutics, Inc. | $8.5M | 1.2% | +13% | — |
| 31 |  $CMPS | COMPASS Pathways plc | $8.3M | 1.2% | NEW | — |
| 32 |  $OCUL | OCULAR THERAPEUTIX, INC | $8.2M | 1.2% | NEW | 12.8 |
| 33 |  $AQST | Aquestive Therapeutics, Inc. | $8.0M | 1.1% | +94% | 11.7 |
| 34 |  $RLMD | RELMADA THERAPEUTICS, INC. | $6.7M | 1.0% | NEW | — |
| 35 |  $ORKA | Oruka Therapeutics, Inc. | $6.5M | 0.9% | +12% | — |
| 36 |  $ZBIO | Zenas BioPharma, Inc. | $6.5M | 0.9% | NEW | 14.4 |
| 37 |  $DRUG | BRIGHT MINDS BIOSCIENCES INC. | $6.3M | 0.9% | +5% | — |
| 38 |  $QDEL | QuidelOrtho Corp | $5.9M | 0.8% | NEW | 26.4 |
| 39 |  $ZBH | ZIMMER BIOMET HOLDINGS, INC. | $5.7M | 0.8% | -84% | 64.9 |
| 40 |  $REPL | Replimune Group, Inc. | $5.5M | 0.8% | NEW | — |
| 41 |  $OGN | Organon & Co. | $5.2M | 0.8% | -75% | 55.1 |
| 42 |  $OKUR | OnKure Therapeutics, Inc. | $4.5M | 0.6% | NEW | — |
| 43 |  $IRON | Disc Medicine, Inc. | $4.2M | 0.6% | +13% | — |
| 44 |  $PMVP | PMV Pharmaceuticals, Inc. | $3.8M | 0.6% | +17% | — |
| 45 |  $IMNM | Immunome Inc. | $3.6M | 0.5% | NEW | 5.8 |
| 46 |  $IART | INTEGRA LIFESCIENCES HOLDINGS CORP | $3.6M | 0.5% | NEW | 31.7 |
| 47 |  $SVRA | Savara Inc | $3.4M | 0.5% | +0% | — |
| 48 |  $CNCPUT | CENTENE CORP | $3.3M | — | NEW | 52.7 |
| 49 |  $PRQR | ProQR Therapeutics N.V. | $3.2M | 0.5% | -10% | — |
| 50 |  $SI | SHOULDER INNOVATIONS, INC. | $3.1M | 0.4% | -8% | 46.5 |
| 51 |  $OVID | Ovid Therapeutics Inc. | $2.8M | 0.4% | -12% | 13.1 |
| 52 |  $KYMR | Kymera Therapeutics, Inc. | $2.7M | 0.4% | +0% | 29.2 |
| 53 |  $ALGS | Aligos Therapeutics, Inc. | $2.4M | 0.3% | -3% | — |
| 54 |  $CNTX | Context Therapeutics Inc. | $2.4M | 0.3% | -32% | — |
| 55 |  $ANTX | AN2 Therapeutics, Inc. | $2.2M | 0.3% | NEW | — |
| 56 |  $SER | Serina Therapeutics, Inc. | $1.9M | 0.3% | NEW | — |
| 57 |  $IBIO | iBio, Inc. | $1.7M | 0.3% | +22% | — |
| 58 |  $ADGM | Adagio Medical Holdings, Inc. | $1.5M | 0.2% | +0% | — |
| 59 |  $XLO | Xilio Therapeutics, Inc. | $1.3M | 0.2% | -93% | 26.9 |
| 60 |  $BBOT | BridgeBio Oncology Therapeutics, Inc. | $1.2M | 0.2% | +0% | — |
| 61 |  $HYPR | Hyperfine, Inc. | $1.1M | 0.2% | -50% | — |
| 62 |  $SENS | Senseonics Holdings, Inc. | $771,121 | 0.1% | +0% | 26.7 |
| 63 |  $FHTX | Foghorn Therapeutics Inc. | $587,409 | 0.1% | +0% | 11.2 |
| 64 |  $TERN | Terns Pharmaceuticals, Inc. | $532,472 | 0.1% | +0% | — |
| 65 |  $ENTA | ENANTA PHARMACEUTICALS INC | $505,200 | 0.1% | +0% | 15.5 |
| 66 |  $TELA | TELA Bio, Inc. | $394,506 | 0.1% | +0% | 24.9 |
| 67 |  $NMTC | NEUROONE MEDICAL TECHNOLOGIES Corp | $385,621 | 0.1% | -56% | — |
| 68 |  $BOLD | Boundless Bio, Inc. | $180,047 | 0.0% | +0% | — |
| 69 |  $NYXH | Nyxoah SA | $148,450 | 0.0% | +0% | — |
| 70 |  $MODD | Modular Medical, Inc. | $138,283 | 0.0% | -97% | — |
| 71 |  $ELTXPUT | Elicio Therapeutics, Inc. | $125,073 | — | -96% | — |
| 72 |  $ERAS | Erasca, Inc. | $80,900 | 0.0% | NEW | — |
| 73 |  $OSCRPUT | Oscar Health, Inc. | $34,410 | — | NEW | 70.4 |
| 74 |  $RCKT | ROCKET PHARMACEUTICALS, INC. | $7,020 | 0.0% | +0% | — |
| 75 |  $HUMA | Humacyte, Inc. | $4,572 | 0.0% | +0% | 5 |
| 76 |  $SLP | Simulations Plus, Inc. | $2,364 | 0.0% | NEW | 37.4 |
New Positions (22)
$CORT CORCEPT THERAPEUTICS INC$27.2M$GSK GSK plc$21.3M$ABT ABBOTT LABORATORIES$19.2M$EMBC Embecta Corp.$16.3M$SION Sionna Therapeutics, Inc.$11.8M$MNPR Monopar Therapeutics$9.5M$EYPT EyePoint, Inc.$9.3M$CMPS COMPASS Pathways plc$8.3M$OCUL OCULAR THERAPEUTIX, INC$8.2M$RLMD RELMADA THERAPEUTICS, INC.$6.7M$ZBIO Zenas BioPharma, Inc.$6.5M$QDEL QuidelOrtho Corp$5.9M$REPL Replimune Group, Inc.$5.5M$OKUR OnKure Therapeutics, Inc.$4.5M$IMNM Immunome Inc.$3.6MExited Positions (14)
$CI Cigna Group
$RYTMPUT RHYTHM PHARMACEUTICALS, INC.
$KVUE Kenvue Inc.
$BTSG BrightSpring Health Services, Inc.$CNC CENTENE CORP
$CRL CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
$MCK MCKESSON CORP
$FULC Fulcrum Therapeutics, Inc.
$VTYX Ventyx Biosciences, Inc.
$ALKS Alkermes plc.
$IDYA IDEAYA Biosciences, Inc.
$OTLKPUT Outlook Therapeutics, Inc.
$AVTX Avalo Therapeutics, Inc.
$NXTC NextCure, Inc.Browse Top Institutional Investors
13F Pro tracks 8,700+ institutional investors filing 13F reports with the SEC.
to search all 8,700+ institutional filers.
Available Analysis
13F Pro tracks comprehensive institutional data for Sio Capital Management, LLC including:
Track Sio Capital Management, LLC's Full Portfolio
See every holding, quarter-over-quarter changes, sector allocation, and accumulation patterns for Sio Capital Management, LLC and 8,700+ other institutional investors.
Free tier includes full 13F search and fund profiles. Pro starts at $6.67/mo (billed annually).
AI-Powered Hedge Fund Analysis: Sio Capital Management, LLC
13F Pro is an AI hedge fund tracker and stock research platform. For Sio Capital Management, LLC (SEC CIK: 1482416), the platform ingests every quarterly Form 13F filing and applies AI-powered analysis on top — 10 specialized AI analysts (value, growth, momentum, macro, activist, and more) debate the fund's top positions and publish AI-generated analysis with cited SEC sources.
Every holding in Sio Capital Management, LLC's portfolio is scored on a 32-signal AI quality ranking (ROIC, FCF margin, revenue growth, institutional flow, earnings quality, shareholder dilution, and more). Track accumulation and distribution quarter over quarter, identify conviction positions, and see AI stock analysis for each position — alongside 8,700+ other institutional filers and 2,800+ AI-ranked companies.